Heterogeneity in the genetic landscape of pediatric acute myeloid leukemia (AML) makes personalized medicine challenging. As genetic events are mediated by the expression and function of proteins, recognition of recurrent protein patterns could enable classification of pediatric AML patients and could reveal crucial protein dependencies. This could help to rationally select combinations of therapeutic targets. To determine whether protein expression levels could be clustered into functionally relevant groups, custom reverse-phase protein arrays were performed on pediatric AML (n = 95) and CD34(+) normal bone marrow (n = 10) clinical specimens using 194 validated antibodies. To analyze proteins in the context of other proteins, all proteins ...
“Big omics data” provoke the challenge of extracting meaningful information with clinical benefit. H...
Acute Myeloid Leukemia (AML) is a heterogeneous disease with several recurrent cytogenetic abnormali...
Intra-tumor heterogeneity caused by clonal evolution is a major problem in cancer treatment. To addr...
Heterogeneity in the genetic landscape of pediatric acute myeloid leukemia (AML) makes personalized ...
Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and the second...
Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and the second...
Despite impressive improvements in overall survival, (pediatric) acute leukemia remains a life-threa...
Pediatric acute myeloid leukemia (AML) remains a fatal disease for at least 30% of patients, stressi...
Acute myeloid leukemia (AML) is believed to arise from leukemic stem-like cells (LSC) making underst...
BACKGROUND: Still 30-40% of pediatric acute myeloid leukemia (pedAML) patients relapse. Delineation ...
Because protein function regulates the phenotypic characteristics of cancer, a functional proteomic ...
The majority of acute myeloid leukemia (AML) patients suffer from relapse and the exact etiology of ...
Globally, 15-20% of all children diagnosed with leukemia suffer from acute myeloid leukemia (AML), a...
The effective treatment of patients in certain subgroups of pediatric acute myeloid leukemia (AML) a...
Acute myeloid leukemia (AML) is believed to arise from leukemic stem-like cells (LSC) making underst...
“Big omics data” provoke the challenge of extracting meaningful information with clinical benefit. H...
Acute Myeloid Leukemia (AML) is a heterogeneous disease with several recurrent cytogenetic abnormali...
Intra-tumor heterogeneity caused by clonal evolution is a major problem in cancer treatment. To addr...
Heterogeneity in the genetic landscape of pediatric acute myeloid leukemia (AML) makes personalized ...
Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and the second...
Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and the second...
Despite impressive improvements in overall survival, (pediatric) acute leukemia remains a life-threa...
Pediatric acute myeloid leukemia (AML) remains a fatal disease for at least 30% of patients, stressi...
Acute myeloid leukemia (AML) is believed to arise from leukemic stem-like cells (LSC) making underst...
BACKGROUND: Still 30-40% of pediatric acute myeloid leukemia (pedAML) patients relapse. Delineation ...
Because protein function regulates the phenotypic characteristics of cancer, a functional proteomic ...
The majority of acute myeloid leukemia (AML) patients suffer from relapse and the exact etiology of ...
Globally, 15-20% of all children diagnosed with leukemia suffer from acute myeloid leukemia (AML), a...
The effective treatment of patients in certain subgroups of pediatric acute myeloid leukemia (AML) a...
Acute myeloid leukemia (AML) is believed to arise from leukemic stem-like cells (LSC) making underst...
“Big omics data” provoke the challenge of extracting meaningful information with clinical benefit. H...
Acute Myeloid Leukemia (AML) is a heterogeneous disease with several recurrent cytogenetic abnormali...
Intra-tumor heterogeneity caused by clonal evolution is a major problem in cancer treatment. To addr...